1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Brain Tumor Drugs Market, By Therapy
5.1 Introduction
5.2 Targeted Therapy
5.3 Chemotherapy
5.4 Immunotherapy
5.5 Other Therapies
6 Global Brain Tumor Drugs Market, By Indication
6.1 Introduction
6.2 Pituitary Tumors
6.3 Meningioma
6.4 Glioblastoma
6.5 Glioma
7 Global Brain Tumor Drugs Market, By Drugs
7.1 Introduction
7.2 Bevacizumab
7.3 Temozolomide
7.4 Other Drugs
8 Global Brain Tumor Drugs Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 F. Hoffmann-La Roche Ltd
10.2 Merck & Co. Inc.
10.3 Pfizer Inc
10.4 Novartis AG
10.5 Amneal Pharmaceuticals LLC.
10.6 NextSource Pharmaceuticals, LLC
10.7 Amgen Inc
10.8 Bristol-Myers Squibb
10.9 Emcure Pharmaceuticals
10.10 AstraZeneca
List of Tables
Table 1 Global Brain Tumor Drugs Market Outlook, By Region (2020-2028) ($MN)
Table 2 Global Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 3 Global Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 4 Global Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 5 Global Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 6 Global Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 7 Global Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 8 Global Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 9 Global Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 10 Global Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 11 Global Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 12 Global Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 13 Global Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 14 Global Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 15 Global Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
Table 16 North America Brain Tumor Drugs Market Outlook, By Country (2020-2028) ($MN)
Table 17 North America Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 18 North America Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 19 North America Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 20 North America Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 21 North America Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 22 North America Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 23 North America Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 24 North America Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 25 North America Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 26 North America Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 27 North America Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 28 North America Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 29 North America Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 30 North America Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
Table 31 Europe Brain Tumor Drugs Market Outlook, By Country (2020-2028) ($MN)
Table 32 Europe Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 33 Europe Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 34 Europe Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 35 Europe Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 36 Europe Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 37 Europe Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 38 Europe Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 39 Europe Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 40 Europe Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 41 Europe Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 42 Europe Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 43 Europe Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 44 Europe Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 45 Europe Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
Table 46 Asia Pacific Brain Tumor Drugs Market Outlook, By Country (2020-2028) ($MN)
Table 47 Asia Pacific Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 48 Asia Pacific Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 49 Asia Pacific Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 50 Asia Pacific Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 51 Asia Pacific Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 52 Asia Pacific Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 53 Asia Pacific Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 54 Asia Pacific Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 55 Asia Pacific Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 56 Asia Pacific Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 57 Asia Pacific Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 58 Asia Pacific Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 59 Asia Pacific Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 60 Asia Pacific Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
Table 61 South America Brain Tumor Drugs Market Outlook, By Country (2020-2028) ($MN)
Table 62 South America Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 63 South America Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 64 South America Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 65 South America Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 66 South America Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 67 South America Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 68 South America Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 69 South America Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 70 South America Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 71 South America Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 72 South America Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 73 South America Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 74 South America Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 75 South America Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
Table 76 Middle East & Africa Brain Tumor Drugs Market Outlook, By Country (2020-2028) ($MN)
Table 77 Middle East & Africa Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 78 Middle East & Africa Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 79 Middle East & Africa Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 80 Middle East & Africa Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 81 Middle East & Africa Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 82 Middle East & Africa Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 83 Middle East & Africa Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 84 Middle East & Africa Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 85 Middle East & Africa Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 86 Middle East & Africa Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 87 Middle East & Africa Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 88 Middle East & Africa Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 89 Middle East & Africa Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 90 Middle East & Africa Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
| ※参考情報 脳腫瘍治療薬は、脳内に発生する腫瘍の治療に使用される薬剤のことを指します。脳腫瘍は、原発性と転移性に分けられ、原発性は脳組織から発生するもの、転移性は他の部位からのがんが脳に転移したものです。これらの腫瘍は、良性と悪性の形式がありますが、脳内の腫瘍は位置やサイズによって脳の機能に悪影響を及ぼす可能性があるため、早期の診断と治療が重要です。 脳腫瘍治療薬は主に化学療法薬、放射線療法薬、分子標的療法薬、免疫療法薬に分類されます。化学療法薬には、テモゾロミドやアムルビシル、シスプラチンなどがあります。これらはがん細胞の増殖を抑制するために使用されます。特にテモゾロミドは、グリオーマと呼ばれる脳腫瘍の一種に対して特に有効です。 次に、放射線療法薬についてですが、放射線治療は腫瘍の縮小や消失を目指すもので、アルファ線やベータ線などが使用されます。特に重粒子線治療や陽子線治療は、高精度で脳腫瘍を狙って放射線を照射できるため、周囲の正常な組織への影響を最小限に抑えることができる利点があります。 分子標的療法薬は、がん細胞の特定の分子を標的にして作用します。これにより、従来の化学療法とは異なり、健康な細胞へのダメージを減少させることが期待されます。例えば、エルロチニブやラパチニブなどがあり、これらは特定の受容体を阻害することによって腫瘍の成長を抑制します。 免疫療法薬は、体中の免疫系を活性化して腫瘍を攻撃する方法で、近年注目を集めています。チェックポイント阻害剤やCAR-T細胞療法などがあり、これらは免疫細胞が腫瘍を認識しやすくする作用を持ちます。これによって、体内での自己防衛機能を高め、腫瘍細胞の排除を促します。 脳腫瘍治療に関しては、治療薬だけでなく、診断法や画像診断技術も重要です。MRIやCTスキャンは、腫瘍のサイズや正確な位置、周囲の構造との関係を把握することに役立ちます。これにより、適切な治療法を選択するための情報を提供します。 また、最近は個別化医療が進展しており、腫瘍の遺伝子解析を通じて特定の治療薬の適応を調べることができるようになっています。これにより、より効果的で副作用の少ない治療を行うことが可能となり、患者の生存率向上に寄与しています。 脳腫瘍治療薬の開発においては、副作用の軽減や効果の最大化が常に求められています。研究者たちは新たな薬剤の開発に加え、既存の治療法と組み合わせることで、より高い治療効果を目指しています。治療の選択肢が増えることで、患者一人一人に最適な治療を提供できる環境が整いつつあります。 脳腫瘍の治療は、依然として難治性の病気であり、研究が進められています。新しい薬剤や治療法の開発により、将来的にはさらに効果的な治療が期待されます。患者とその家族にとって、希望の光が見えてくる日が来ることを願っています。脳腫瘍治療薬の情報を理解し、治療方針を選択する際には、専門家の意見をもとに方針を立てることが重要です。治療薬の効果やリスクについての詳細な説明を受けることが、適切な治療を選ぶための第一歩となります。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
